Helicobacter Pylori Eradication Therapy in Portugal
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Helicobacter pylori (H. pylori) infection remains a major public health problem, with an
estimated prevalence of over 50% worldwide and 60-86% for Portugal. H. pylori is associated
with significant morbidity and mortality from peptic ulcerative disease to gastric cancer,
whose eradication therapy has proven to be effective in preventing these complications.
Factors involved in the development of these conditions include H. pylori virulence, host
genetic factors and gut microbiota. Given the increasing pattern of antibiotic resistance
evidenced by this bacterium and the scarcity of available antibiotic therapy, both in
Portugal and worldwide, there is not enough evidence on the best eradication strategy.
Regarding the uncertainties about the potential negative impact of indiscriminate use of
eradication therapy on gut microbiota, either by proton pump inhibitors or by antibiotics per
se, there is an overriding need for evidence about the real impact of this therapy on oral or
gut flora and possible clinical consequences in immunological, metabolic, nutritional and
oncological terms.
Objectives: Comparative evaluation of the efficacy of the different quadruple therapy
regimens recommended for the H. pylori eradication. Comparative evaluation of the safety
profile in terms of clinical, and immunological and gut microbiota impact of the different
therapies for the H. pylori eradication.
Phase:
N/A
Details
Lead Sponsor:
Centro Hospitalar e Universitário de Coimbra, E.P.E.